Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Duchenne Muscular Dystrophy (DMD) Drugs Market

Duchenne Muscular Dystrophy (DMD) Drugs Market Share

  • Report ID: GMI10182
  • Published Date: Jul 2024
  • Report Format: PDF

Duchenne Muscular Dystrophy Drugs Market Share

The Duchenne muscular dystrophy (DMD) drugs market is characterized by intense R&D activities focused on innovative therapeutic approaches. The key players in the market are heavily investing in gene therapy, exon skipping drugs, and other advanced technologies to address the genetic mutations underlying DMD. In addition, the market competition is further driven by the pursuit of treatments that improve muscle function and delay disease progression. Furthermore, regulatory approvals, strategic partnerships, and clinical trial outcomes play pivotal roles in shaping market dynamics, influencing market penetration, and competitive positioning of therapies.
 

Duchenne Muscular Dystrophy Drugs Market Companies

Few of the prominent players operating in the Duchenne muscular dystrophy drugs industry include:

  • Aurobindo Pharma
  • Capricor Therapeutics, Inc.
  • Catalyst Pharmaceuticals Inc.
  • EspeRare Foundation
  • FibroGen, Inc.
  • Italfarmaco S.p.A
  • NS Pharma
  • PTC Therapeutics, Inc.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics, Inc.
  • Solid Biosciences Inc.
     
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The duchenne muscular dystrophy drugs market size was valued at USD 3.2 billion in 2023 and is estimated to grow at 11.6% CAGR between 2024 to 2032, driven by increasing burden of DMD and rising demand for novel therapies.

The corticosteroids segment of the market will account for USD 1.2 billion by 2032, attributed to their well-established efficacy in slowing the progression of the disease.

Asia Pacific duchenne muscular dystrophy drugs market held a decent share in 2023 and is poised to grow at 12% CAGR during 2024-2032, driven by increasing awareness and improved diagnostic capabilities.

Aurobindo Pharma, Capricor Therapeutics, Inc, Catalyst Pharmaceuticals Inc, EspeRare Foundation, and FibroGen, Inc. among others.

Duchenne Muscular Dystrophy Drugs Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 311
  • Countries covered: 22
  • Pages: 160
 Download Free Sample